KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.85

Ulinastatin in the treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomized clinical trial.

Xuguang Wang, Haijun Wu, Feng Lei, Zhigang Liu, Guanzhu Shen, Xuefeng Hu, Yijing Ye, Manyi Zhu, Huageng Huang, Boyu Chen, Runda Huang, Chong Zhao, Jingjing Miao, Lin Wang

Nat Commun 16(1) 2848

PMID40122906
PMCIDPMC11930952
DOI10.1038/s41467-025-57884-6
发表日期2025-03-24
入排依据:This is a Phase III randomized clinical trial in oncology (nasopharyngeal carcinoma) with a drug intervention (Ulinastatin) and reports original results on both the primary endpoint (incidence of grade ≥3 RTOM) and key secondary time-to-event efficacy endpoints (OS, LRRFS, DMFS, PFS) at 3 years. The drug is not a generic/biosimilar and is administered in conjunction with standard chemoradiotherapy.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。
摘要

摘要

Radiotherapy-induced oral mucositis (RTOM) is a common side effect of radiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT). In this phase 3 trial, we aim to evaluate the efficacy and safety of Ulinastatin (UTI) for the prevention and treatment of RTOM in LA-NPC patients (NCT03387774). The primary endpoint is the incidence of grade ≥3 acute RTOM during radiotherapy. Secondary endpoints include cumulative incidence of RTOM, recovery rate, the onset time and duration of grade ≥3 RTOM, oral pain (severe), safety and survival outcomes. 179 eligible patients are randomly assigned to UTI Group (n = 89) or Control group (n = 90). All UTI group patients complete UTI treatment as planned, and both groups complete scheduled CCRT. The incidence of grade 3 RTOM is significantly lower in UTI group compared with control group (25.8% vs 41.1%, P = 0.030). The trial meet its prespecified primary endpoint. No Ulinastatin related adverse events are observed during treatment. The 3-year overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) in UTI group and control group are similar between two groups. In this work, Ulinastatin can effectively reduce the severity of RTOM and oral pain without increasing toxicity and compromising survivals.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Trial profile. UTI Ulinastatin, CCRT concurrent chemoradiotherapy, AEs adverse events.
非 KM Figure
Fig. 2Acute oral mucosities by treatment groups. A Incidence of acute oral mucosities for 179 evaluable patients. The difference in incidence of grade 3 RTOM during CCRT between groups was statistically significant ( P = 0.030, two-sided Fisher’s exact test). Statistical note: no adjustments for multiple comparisons were applied, as the analysis focused on pre-specified differences in grade 3 RTOM. B Cumulative rate of grade ≥3 mucositis during treatment in UTI group (89 patients, at 7 weeks 23 at risk), Control Group (90 patients, at 7 weeks 37 at risk). Source data are provided as a Source Data file. *: Significant difference between groups (two-sided Fisher’s exact test; P < 0.05). UTI Ulinastatin.
非 KM Figure
Fig. 3Oral pain by treatment groups. A Incidence of oral pain for 179 evaluable patients. The difference in the incidence of severe oral pain during CCRT between groups was statistically significant ( P = 0.038, two-sided Fisher’s exact test). Statistical note: no adjustments for multiple comparisons were applied, as the analysis focused on pre-specified differences in severe oral pain. B Cumulative rate of severe oral pain during treatment in UTI group (89 patients, at 7 weeks 20 at risk), Control group (90 patients, at 7 weeks 33 at risk). Source data are provided as a Source Data file. *: Significant difference between groups (two-sided Fisher’s exact test; P < 0.05). UTI Ulinastatin.
非 KM Figure